42nd Clinical Applications for Age Management Medicine
Advancing Longevity thru Evidence-Based Strategies and Technology
THE NATIONAL DORAL MIAMI RESORT & SPA | MIAMI, FLORIDA
April 15 – 18, 2027
Select Workshop OR SESSION to View Agenda & Faculty
*Times, Topics, Titles & Faculty Subject To Change
AMA CME Credits Offered for Select Courses
- Thur. Workshop - Essential Knowledge of Peptides - Part 1
- Thur. Workshop - GLP-1 Master Class Training Seminar
- Thur. Workshop - Longevity Medicine Module 1 Primer
- Thur. Workshop - Practice Management
- Friday General Session
- Saturday General Session
- Sun. Workshop - Advanced Peptide Clinical Strategies - Part 2
- Sun. Workshop - Neurotrauma Masterclass - Treating TBI
- Sun. Workshop - Artificial Intelligence in Longevity Medicine
Thursday, April 15th
Essential Knowledge and Updates for the Clinical Use of Peptides - Part 1
This workshop is an 8-hour class on learning Essential Knowledge of Peptide Therapy. The human body produces almost 300,000 peptides, but only a fraction of the peptides that we produce are understood. Dr. Edwin Lee and Dr. Luis Martinez have taught many healthcare providers around the world about the clinical use of peptides. Many previous students have commented that this peptide class was excellent and they felt confident with using peptides in their practice. The use of certain peptides is in a state of flux. As of Sep 2023, the FDA has banned a list of 22 peptides from being produced by 503A compounding pharmacies in the US. By the start of this class, updated lectures will offer alternative peptides to treat specific conditions. Bring your laptop computer to this workshop. At its conclusion, a score of 80% on an optional test taken on your laptop will earn attendees a certificate demonstrating Essential Knowledge of the Clinical Use of Peptides.
Requirement: Bring your laptop computer for the class to take the post workshop examination.
In Conjunction with the Clinical Peptide Society
Non-CME Workshop
TOPICS INCLUDE:
– Introduction to Peptides
– The Wolverine Peptide, BPC-157
– Mitochondria Peptides
– Immune Stimulating Peptides
– Peptides for Autoimmune Diseases
– Growth Hormone Peptides
– Neurodegenerative Peptides
– Peptides for Cancer
– Cosmeceutical Peptides
– Sex Peptides
– Peptides for Pain
– Pineal Peptides
– Melanotan Peptides
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:05 am | Welcome to the Workshop on Essential Knowledge in the Clinical Use of Peptides |
| 8:05 – 8:40 am | Introduction to Peptides Edwin Lee, M.D Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee This session will address the basics of what a peptide is, what receptor does it interact with, how do peptides work, how many peptides do we have and which hormones are peptides. Some peptides are hormones and also neurotransmitters. In addition, how a peptide is synthesized in a lab will be reviewed. The benefits of peptides and where most of the peptides that can be obtained will be covered. In addition, the status of the peptides from the FDA will be reviewed. |
| 8:40 – 9:10 am | The Wolverine Peptide Edwin Lee, M.D. Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee The peptide BPC-157 is a stable 15–amino acid peptide originally derived from a larger protein found in human gastric juice. It was first described by and colleagues in 1993, who identified Body Protection Compound (BPC) and characterized BPC-157 as its biologically active fragment. Since its discovery, Dr. Sikiric and collaborators have published more than 170 scientific articles investigating the peptide’s mechanisms of action and regenerative properties. Although the majority of published data originate from animal and laboratory studies, a limited number of human clinical trials have been conducted. This presentation reviews the history of BPC-157, its proposed mechanisms of action, and the currently available human clinical evidence regarding its safety and efficacy. |
| 9:10 – 9:45 am | Mitochondria Peptide Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Mitochondrial dysfunction is recognized as one of the fundamental hallmarks of aging and contributes to the development of numerous chronic diseases, including metabolic, cardiovascular, and neurodegenerative disorders. Recent advances in mitochondrial biology have led to the discovery of mitochondrial-derived peptides, a novel class of signaling molecules that play important roles in cellular metabolism, stress resistance, and tissue repair. This presentation will review two of the most promising mitochondrial peptides, MOTS-c and SS-31 (Elamipretide), highlighting their mechanisms of action, preclinical and clinical research, and potential therapeutic applications in age-related diseases. Available human data, dosing strategies, safety profiles, and reported adverse effects will also be discussed. |
| 9:45 – 10:00 am | Break |
| 10:00 – 10:30 am |
Immune Stimulating Peptides Thymic peptides play a critical role in immune regulation and have been investigated for their ability to enhance immune function, reduce inflammation, and improve resistance to infections. This presentation will review two of the most widely studied thymic peptides, Thymosin Alpha 1 and Thymulin, with an emphasis on their mechanisms of action, clinical applications, and published human studies. Available evidence regarding dosing protocols, safety profiles, and therapeutic outcomes will be discussed. In light of ongoing regulatory challenges and potential limitations in access to Thymosin Alpha 1, an alternative peptide will also be reviewed as potential strategy to support immune health and optimize immune function. |
| 10:30 – 11:00 am | Peptides for Autoimmune Diseases Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Autoimmune diseases are increasing in prevalence and are driven by an imbalanced immune response. This presentation will review four immune-modulating peptides—Thymosin Alpha 1 , Met-Enkephalin, Vasoactive Intestinal Peptide and KPV—and their potential roles in restoring immune balance and reducing inflammation. Available clinical evidence, mechanisms of action, dosing protocols, and safety considerations will be discussed. |
| 11:00 – 11:30 am | Growth Hormone Peptides Edwin Lee, M.D. Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Growth hormone is an essential hormone in lowering body fat, improving on lipids, keeping muscles healthy and improving on bone density. Adult growth hormone deficiency symptoms will be reviewed and the association of higher mortality with growth hormone deficiency. Unfortunately, the treatment with recombinant human growth hormone is not covered under most insurance plans and also it is cost prohibitive for most people. There is an alternative to the expensive recombinant human growth hormone mostly commonly used for boosting IGF-1 and has the advantage of inducing all five of the hGH isoforms rather just the one that is found in the synthetic form. Tesamorelin, Sermorelin and others are peptides will be reviewed. |
| 11:30 am – 12:00 pm | Neurodegenerative Peptides Edwin Lee, M.D. Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Memory loss and cognitive decline are among the most significant health concerns associated with aging. While there is no single solution for preventing or reversing cognitive impairment, a comprehensive functional medicine approach may help optimize brain health. Key strategies include hormonal optimization, improving gut microbiome health, reducing systemic inflammation, correcting nutritional deficiencies, and identifying and removing environmental toxins that may contribute to neurodegeneration. This presentation will review several neuropeptides and neuroregenerative compounds that have shown promise in supporting cognitive function, including Cerebrolysin, Semax, Selank, and Thymosin Beta 4. The proposed mechanisms of action, available preclinical and clinical evidence, dosing protocols, safety profiles, and potential therapeutic applications for cognitive health and neuroprotection will be discussed. |
| 12:00 – 1:30 pm | Lunch Break |
| 12:00 – 1:00 pm | Lunch |
| 1:30 – 2:00 pm | Peptides for Cancer Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Cancer remains one of the leading causes of death worldwide. Emerging peptide therapies may offer novel approaches to cancer management by enhancing immune surveillance, supporting the body’s natural defenses against malignant cells, and modulating cellular pathways involved in tumor growth and suppression. This presentation will review met-enkephalin, GHK, thymosin alpha 1, and other peptides with potential anticancer properties. Available research, proposed mechanisms of action, dosing strategies, safety profiles, and potential clinical applications will be discussed. |
| 2:00 – 2:30 pm | Cosmeceutical Peptides Edwin Lee, M.D. Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Aging of the skin is characterized by a decline in collagen production, loss of elasticity, and reduced fibroblast activity. Emerging peptide therapies may help support skin rejuvenation by stimulating fibroblasts, enhancing collagen synthesis, and improving overall skin quality. This presentation will review several cosmetic and regenerative peptides, including GHK-Cu, Matrixyl, and Botox-like peptides, with a focus on their mechanisms of action, available clinical evidence, dosing strategies, and safety considerations for promoting a more youthful appearance. |
| 2:30 – 2:45 pm | Sex Peptides Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Sexual health and libido can be influenced by a variety of factors, including hormonal balance, stress, emotional well-being, and vascular function. Emerging peptide therapies may offer novel approaches to enhancing sexual desire, arousal, and intimacy. This presentation will review peptides such as PT-141 and oxytocin, focusing on their mechanisms of action, available clinical evidence, dosing strategies, safety profiles, and potential roles in supporting sexual health and improving libido in both men and women. |
| 2:45 – 3:00 pm | Peptides for Pain Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Chronic pain remains a significant challenge and often responds incompletely to conventional therapies. This presentation will review the peptides ARA-290, KPV, BPC-157, Thymosin Beta-4 (TB4), and Met-Enkephalin, which may help reduce pain through anti-inflammatory, regenerative, immune-modulating, and neuroprotective mechanisms. Available human and preclinical studies, proposed mechanisms of action, and safety considerations will be discussed. Participants will gain practical insights into the potential role of these peptides in the management of neuropathic, inflammatory, and musculoskeletal pain conditions. |
| 3:00 – 3:15 pm | Break/Visit Exhibits |
| 3:15 – 4:00 pm | Pineal Peptides Edwin Lee, M.D. Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Pineal peptides have attracted growing interest for their potential roles in healthy aging, longevity, and cognitive function. This presentation will review two of the most extensively studied pineal peptides, Epitalon and Pinealon. Research on Epitalon suggests potential effects on telomere biology, gene expression, healthy aging, and longevity in both animal and human studies. Pinealon, a related peptide, has been investigated for its neuroprotective properties and potential benefits in supporting cognitive function, including recovery following traumatic brain injury. Available research, proposed mechanisms of action, dosing strategies, safety profiles, and potential clinical applications will be discussed. |
| 4:00 – 4:30 pm | Melanotan Peptides and Q & A Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Melanocortin peptides have gained attention for their potential effects on skin pigmentation, sexual health, and appetite regulation. This presentation will review Melanotan I, Melanotan II, and PT-141, focusing on their mechanisms of action, clinical applications, and available research. Dosing strategies, safety profiles, potential adverse effects, and regulatory considerations will also be discussed. |
| 4:30 – 5:30 pm | Online Test Essential Knowledge in Clinical Use of Peptides Test – Requires a Laptop |
| 5:30 – 7:00 pm | AMMG Exhibit Hall Happy Hour Open to all conference attendees, spouses and guests Held in Conference Networking and Exhibits Center |
Thursday, April 15th
GLP-1 Master Class Training Seminar
This seminar is designed as a comprehensive clinical course for physicians and healthcare professionals to give clinicians a deep, clinically actionable mastery of GLP 1–based therapies—far beyond the usual weight loss framing. The course blends physiology, pharmacology, risk management, and real world clinical practice so physicians can confidently evaluate, prescribe, monitor, and discontinue GLP 1 medications with precision. Physicians will leave with a command of GLP 1 mechanisms, comparative drug profiles, safety considerations, testing protocols, patient selection, and long term treatment strategy—plus clarity on the misconceptions that commonly lead to suboptimal outcomes.
CME Workshop
TOPICS INCLUDE:
– Background of GLP-1 & Mechanisms of Action
– Comparing the GLP-1s
– Beyond Weight Loss
– Common Concerns & the Most Common Things Health Care Providers May be Getting Wrong
– Complications & What the Health Care Professional Needs to Know
– The Consenting Process and Initial Examination : What you NEED to do vs “Curious” to do. Essential components in History taking and Documentation
– Adjunctive Testing & Clinical Recommendations
– The Allure of “Triple-G” & New GLP-1s Coming Down the Pipeline
– Stopping Treatment — Now What?
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:50 am | Background of GLP-1 & Mechanisms of Action Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY History (exenatide to semaglutide and tirzepatide); effects on multiple organ systems (pancreas, GI tract, liver, heart and blood vessels, kidneys, fat tissue); overview of neurobiology (appetite and satiety centers in the hypothalamus and brainstem, reward pathways) |
| 8:50 – 9:30 am | Comparing the GLP-1s Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY Semaglutide, tirzepatide and oral options; effectiveness, dosing, and schedules |
| 9:30 – 10:15 am | Beyond Weight Loss Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY Heart and kidney benefits, MASH (fatty liver), sleep apnea, arthritis, and emerging uses such as addiction, depression, and observational signals |
| 10:15 – 10:30 am | Break |
| 10:30 – 11:15 am | Common Concerns & the Most Common Things Health Care Providers May Be Getting Wrong Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY Systemic side effects, titration mistakes, muscle loss : are we “freaking ourselves out?’ “Ozempic face,” compounded products, microdosing, HSCRP “clinic” and GLP1 vs. Statin Therapy |
| 11:15 am – 12:00 pm | Complications & What the Health Care Professional Needs to Know Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY Pancreatitis, gallbladder disease, gastroparesis/ileus, aspiration risk with anesthesia, thyroid C-cell warnings, NAION (eye), diabetic retinopathy, hair loss and other concerns. |
| 12:00 – 1:30 pm | Lunch Break |
| 1:30 – 2:15 pm | Lunch |
| 2:15 – 3:00 pm | Adjunctive Testing & Clinical Recommendations Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY Baseline labs, body composition, monitoring schedule, nutrition, protein and resistance training. Recommendations that “won’t break the Bank’. |
| 3:00 – 3:45 pm | Break/Visit Exhibits |
| 3:45 – 4:30 pm | The Allure of “Triple-G” & New GLP-1s Coming Down the Pipeline Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY Retatrutide, which acts on three hormone receptors (GLP-1, GIP and glucagon); oral small molecules; amylin combinations such as CagriSema; monthly dosing |
| 4:30 – 5:30 pm | Stopping Treatment? – Now What? Joshua S. Fink, M.D., NBPAS Private Practice, Mt. Kisco, NY Weight regain, tapering strategies, maintenance dosing, transitioning to lifestyle-only care and when to re-initiate |
| 5:30 – 7:00 pm | AMMG Exhibit Hall Happy Hour
Open to all conference attendees, spouses and guests Held in Conference Networking and Exhibits Center |
Thursday, April 15th
Workshop: Primer for Physicians and Healthcare Professionals New to Age Management and Longevity Medicine and those in the AMMG Module 1 Certification Program
This workshop is designed to familiarize physicians and healthcare professionals with limited experience with the basics and core issues in Age Management & Longevity Medicine. Covers Patient evidence based Assessment Protocols, Men’s and Women’s Hormones, Nutrition, Supplements, Fitness & Exercise and emerging precision medicine as it applies to the aging patient. In addition this workshop will serve as a primer for those healthcare professionals currently enrolled in the AMMG Certification Program that need to study for the Module 1 examination. Faculty have been asked to cover info on the actual test questions however they will not be providing the actual question and answer only covering the information regarding this.
CME Workshop
TOPICS INCLUDE:
– Nutrition & Supplements
– Patient Assessment
– Fitness & Exercise
– Motivating Patients
– Hormones – DHEA, Growth Hormone, Insulin Growth-like Factor-1 (IFG-1) Pregnenolone, Legal Issues in the Use of Hormones Specifically Testosterone and Growth Hormone
– Hormone Optimization Therapies: Dihydrotestosterone (DHT), Testosterone (T), Estrogen, Human Chorionic Gonadotropin (hCG), Progesterone
– Hormone Optimization Therapies: Cortisol, Insulin, Thyroid, Environmental Influences on Hormones
– Emerging Therapies for Age Management/Longevity in Precision Medicine
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:45 am | Nutrition and Supplements Derrick DeSilva, Jr., M.D. Associate Attending Staff Raritan Bay Medical Center, Perth Amboy, NJ Board of Directors American Univ. School of Medicine Aruba Recipient, Alan Mintz Award for Clinical Excellence Lecture Description TBA |
| 8:45 – 9:30 am |
Patient Assessment Lecture Description TBA |
| 9:30 – 10:15 am | Fitness & Exercise Todd Fox Director of Clinical Operations, Better Life Carolinas Lecture Description TBA |
| 10:15 – 10:30 am | Break |
| 10:30 – 11:00 am | Motivating Patients William Clearfield, D.O., FAAMA, DABMA, FAARFM Medical Director, Clearfield Family Medicine, Reno, NV Executive Director, American Osteopathic Society of Rheumatic Diseases Adjunct Professor, Arkansas College of Osteopathic Medicine; University of Guadalajara School of Medicine Lecture Description TBA |
| 11:00 am – 12:00 pm | Hormones – DHEA, Growth Hormone, Insulin Growth-like Factor-1 (IFG-1), Pregnenolone, Legal Issues in the Use of Hormones Specifically Testosterone and Growth Hormone Mark L. Gordon, M.D. Medical Director, Millennium – TBI & The Millennium Health Centers, Encino, CA; CBS Studios Department of Family Medicine, USC, Keck School of Medicine, Los Angeles, CA (1997-2013) Medical Director of Education, Access Medical Laboratories, Jupiter, FL Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Conference Planning Committee Lecture Description TBA |
| 12:00 – 1:30 pm | Lunch Break |
| 12:00 – 1:00 pm | Lunch |
| 1:30 – 3:00 pm | Hormone Optimization Therapies: Dihydrotestosterone (DHT), Testosterone (T), Estrogen, Human Chorionic Gonadotropin (hCG), Progesterone Rob Kominiarek, D.O., FACOFP Director, ReNue Health, Springboro, OH Assistant Clinical Professor, Ohio University College of Osteopathic Medicine Member, AMMG Planning Committee Lecture Description TBA |
| 3:00 – 3:45 pm | Break/Visit Exhibits |
| 3:45 – 4:45 pm | Hormone Optimization Therapies: Cortisol, Insulin, Thyroid, Environmental Influences on Hormones William Clearfield, D.O., FAAMA, DABMA, FAARFM Medical Director, Clearfield Family Medicine, Reno, NV Executive Director, American Osteopathic Society of Rheumatic Diseases Adjunct Professor, Arkansas College of Osteopathic Medicine; University of Guadalajara School of Medicine Lecture Description TBA |
| 4:45 – 5:30 pm | Emerging Therapies for Age Management/Longevity in Precision Medicine Daniel L. Stickler, M.D. Co-Founder & CMO, Apeiron Center for Human Potential Chief Science Officer, Apeiron Academy Lecture Description TBA |
| 5:30 – 7:00 pm | AMMG Welcome Reception
Open to all conference attendees, spouses and guests Held in Conference Networking and Exhibits Center |
Thursday, April 15th
Workshop: Practice Management - Launching and Growing a Successful Age Management Practice
Many attendees of the AMMG conferences are attracted to the field of Age Management Medicine, but do not feel qualified, or empowered with the necessary tools, to successfully transition from the well-established structure of disease-based medicine or from the traditional insurance-based reimbursement system into a system which relies to a significant degree upon direct pay. In addition, this workshop is also designed to complement the AMMG Certification in Age Management Medicine for physicians and healthcare professionals and to help educate and inform medical and office staff. Attendees will be guided through the process of developing or growing an Age Management Practice. Our goal is for the attendee to be equipped with the basic tools for making the necessary decisions on what is required from a Practice Management point of view.
Non-CME Workshop
TOPICS INCLUDE:
– The Direct Pay/Partial Direct Pay Practice Model
– Development of Practice Services and Procedures
– Development of Diagnostic Tools and Procedures
– Creating Revenue Through the Sales of Ancillary Products and Services from Your Office
– Motivating Patients and Creating Programs Applying the Science of Age Management Medicine to Produce Positive Patient Outcomes
– The AI – Powered Medical Practice: How to Save Hundreds of Staff Hours and Scale without Adding Employees
– Marketing to Age Management/Longevity Patients
– Marketing your Practice Using Social Media
– Financial Literacy & Understanding Financial Statements: Why They Matter in Running Your Medical Practice
– Building a Defensible Age Management Practice
– Practice Landmines & Practice Pearls
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:40 am | The Direct Pay/Partial Direct Pay Practice Model Chuck Guglin, M.D., FACS Owner, Hyperfit MD Age Management Center Understand what a direct pay practice is, learn what the best practices for this type of practice are and transcend the fear of moving from insurance-based to direct pay practice. Attendees will be asked to envision the ideal Age Management practice they wish to develop. |
| 8:40 – 9:20 am | Development of Practice Services and Procedures Chuck Guglin, M.D., FACS Owner, Hyperfit MD Age Management Center Understand the range of services than can be offered from an Age Management practice and understand how you can develop a menu of services that will fit you and your practice. |
| 9:20 – 10:00 am | Development of Diagnostic Tools and Procedures Chuck Guglin, M.D., FACS Owner, Hyperfit MD Age Management Center Diagnosing the Age Management patient is critical to formulation of a personalized patient treatment plan. This lecture will provide attendees with options regarding diagnostic tools and procedures. |
| 10:00 – 10:15 am | Break |
| 10:15 – 11:15 am | Creating Revenue Through the Sales of Ancillary Products and Services from Your Office Derrick DeSilva, Jr., M.D. Associate Attending Staff, Raritan Bay Medical Center, Perth Amboy, NJ Board of Directors, American University School of Medicine, Aruba Recipient, Alan Mintz Award for Clinical Excellence We have a captive audience with the patients we see every day. They trust our judgments and that is why they seek us out for their medical care. The trust can be translated into other products and services that we provide in our clinical practice—everything from cosmetic products and procedures to carrying a line of high quality nutraceuticals. The educational process to “sell” these products and services does take some upfront time. Once the patient/consumer becomes part of the process to utilize these products and services it can become a critical recurrent part of your revenue stream. The questions is, what products and services should you offer and how do you decide what these products and services should be? During this presentation I will help you outline how to start with the basics and in time build/create that revenue stream even when you are not physically seeing the patient. |
| 11:15 am – 12:00 pm | Motivating Patients and Creating Programs Applying the Science of Age Management Medicine to Produce Positive Patient Outcomes Faculty TBA Lecture Description TBA |
| 12:00 – 1:00 pm | Lunch Break |
| 12:00 – 12:30 pm | Lunch |
| 1:00 – 1:40 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 1:40 – 2:30 pm | Marketing to Age Management/Longevity Patients Doug Roper, M.D. Chief Medical Officer, Arthritis, Knee Pain Centers Lecture Description TBA |
| 2:30 – 3:15 pm | Break |
| 2:45 – 3:30 pm | Marketing your Practice Using Social Media Bobby Macey CEO, Macey Media Lecture Description TBA |
| 3:15 – 3:45 pm | Break/Visit Exhibits |
| 3:45 – 4:45 pm | Financial Literacy & Understanding Financial Statements: Why They Matter in Running Your Medical Practice John Rush, M.D., MBA Chairman & CEO, Arthritis Knee Pain Centers Lecture Description TBA |
| 4:45 – 5:15 pm | Building a Defensible Age Management PracticeChuck Guglin, M.D., FACS Owner, Hyperfit MD Age Management Center Identify and discuss six areas of Practice Risk: Documentation, Data Security and AI, Clinical Protocols & Off Label Prescribing, Billing, Marketing and Fraud Avoidance, Controlled Substance and DEA Compliance, Business Structure and Scope of Practice, Records, Facility & Staff Compliance. |
| 5:15 – 5:30 pm | Practice Landmines & Practice Pearls Chuck Guglin, M.D., FACS Owner, Hyperfit MD Age Management Center Learn what to avoid to eliminate or reduce the inevitable problems, and those pearls from experienced Practice Management Professionals that can help you succeed. |
| 5:30 – 7:00 pm | AMMG Welcome Reception
Open to all conference attendees, spouses and guests Held in Conference Networking and Exhibits Center |
Friday, April 16
Friday General Session
– Peptides and Men’s Health
– Beyond Weight Loss: The Role of Nutrition in Restoring Metabolic and Liver Health
– Longevity: Hope, Hype and Science, Peptide Bioregulators
– A New Ecology of Menopause: The Microbiome & GSM
– The Future of Artificial Intelligence in Preventive Medicine
– Why Diabetes Treatment Fails?
– You Can’t Outperform an Overloaded Nervous System: Rethinking the HRT Plateau
AMA CME Credits Offered for Select Courses
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:10 am | Opening Remarks |
| 8:10 – 9:10 am | Traditional Pharmacotherapy — The Myth of Living Longer Luis Martínez, M.D. President, XanoGene Clinic, San Juan, Puerto Rico President, Regenera Global, Ponce, Puerto RicoFor decades, traditional pharmacotherapy has been sold as the engine of better health and longer life. Yet when stripped of the marketing rhetoric and relative risk spin, the evidence tells a far less inspiring story: most widely prescribed medications do almost nothing to extend human lifespan. Statins, antihypertensives, antiplatelets, glucose-lowering agents, and countless other “preventive” drugs deliver striking improvements only on paper—dramatic relative risk reductions that mask microscopic absolute gains. For most patients, especially those without severe disease, these interventions add little more than days to months of life, often at the cost of side effects, polypharmacy, and medicalization of the otherwise healthy. Traditional pharmacotherapy excels at altering laboratory numbers yet fails to meaningfully modify the fundamental biology aspects of aging: mitochondrial dysfunction, metabolic rigidity, hormonal decline, and loss of cellular resilience among others. Meanwhile, interventions grounded in physiology—lifestyle optimization, hormonal restoration, regenerative therapies, metabolic optimization—show a far greater potential to shift the trajectory of aging than any pill designed to tweak a surrogate marker. The belief that more pharmaceuticals equal more life is not only scientifically unsubstantiated, it is one of the most persistent illusions in modern medicine. A paradigm shift, which is overdue, will be presented in this lecture. |
| 9:10 – 10:15 am | The Role of Metabolic Engineering in the Treatment of Chronic Disease and Aging (NON CME LECTURE) Barry Sears, PhD President, Barry Sears Inflammation Research Foundation, Peabody, MA Voluntary Assistant Professor of Surgery, University of Miami Medical School Adjunct Faculty, School of Nutrition and Health Promotion, College of Health Solutions, Arizona State UniversityThe underlying cause of chronic disease and aging is metabolic dysfunction. At the cellular level, this is ultimately caused by dysregulation of the epigenetic control of key metabolic pathways. AMPK, the master regulator of metabolism, ultimately regulates these pathways. Any inhibition of AMPK activity will manifest itself in earlier development of chronic disease conditions associated with insulin resistance and the acceleration of cellular senescence. Metabolic Engineering is an integrated dietary program composed of a highly defined calorie restriction program coupled with adequate omega-3 fatty acid and polyphenol supplementation to activate AMPK and maintain it within a therapeutic zone necessary to epigenetically reprogram a disrupted metabolism. Published clinical data will be discussed. |
| 10:15 – 11:00 am | Break/Visit Exhibits |
| 11:00 – 11:45 am | Practical Applications for Supporting Immune Health – (NON CME LECTURE) Maureen Pickle, DMSc, MPH, PA-C Clinical Science Liaison Women’s Health Specialist, NovonesisDr. Maureen Pickle, DMSc, MPH, PA-C, will present Practical Applications for Supporting Immune Health, offering dynamic insight into the multilayered immune defense network. Dr. Pickle will cover the latest advancements in immune health, focusing on the gut-lung axis and the role of probiotics and more specifically immunobiotics in enhancing immune function. Key topics include the impact of respiratory and digestive microbiomes on overall health, the benefits of specific probiotic strains like LGG® and BB-12®, and fermentation products designed for daily immune support. The presentation also highlights clinical studies demonstrating the effectiveness of immunobiotics in supporting respiratory comfort and boosting immune responses. This comprehensive overview aims to provide practical insights for healthcare professionals to support immune health in their patients. |
| 11:45 am – 12:00 pm | Why Undergo Certification in Age Management Medicine James Powell, R.N. AMMG Certification Specialist |
| 12:00 – 1:30 pm | Lunch Break/Visit Exhibits |
| 12:00 – 1:00 pm | Lunch |
| 1:30 – 2:15 pm | Demystifying Endotoxin: Identifying and Quenching the Fire Within-Clinical Tools to Reverse Neuroinflammation and LPS Burden Thomas O’Bryan, D.C., CCM. DACBN, CIFM Adjunct Faculty, The Institute for Functional Medicine, National University of Health Sciences, Integrative and Functional Nutrition AcademyEditorial Review Board, Journal of International Medicine, Therapies in Health and Medicine Scientific Advisory Board, Institute for Responsible Technology Clinical Concierge Health Care PracticeThis practical, high-impact lecture expands on the foundational science of endotoxin (lipopolysaccharides, LPS) and focuses on clinical application: how to assess, intervene, and restore resilience in patients whose healthspan is silently eroding under the weight of chronic LPS driven inflammation. We begin with comprehensive strategies to identify the magnitude and scope of LPS burden—not just in the gut, but where it matters most: the brain. Although the brain represents only 2% of total body mass, it carries up to 18% of total blood flow at any one time, and is one of the earliest sites to reflect immune-mediated damage. Biomarkers of neuroinflammation, blood–brain barrier permeability, and immune overactivation will be explored, with clear guidance on when and how to use them. From there, we will explore multi-phased, integrative protocols to:
This is more than an academic review. It is a call to clinical action providing participants with the lab, interpretation tools, and layered therapeutic frameworks to implement Monday morning. |
| 2:15 – 3:00 pm | Precision Diagnostics Unveils Metabolic Dysfunction: Applying Nof1 Medicine For All Decades of Life Florence Comite, M.D. Owner & CMO, Comite Center for Precision Medicine, New York, NY Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning CommitteeMetabolic dysfunction develops years before emerging symptoms of disease. Precision diagnostics, including metabolomic profiling, advanced lipid panels, and genomic insights, enable us to detect biological abnormalities throughout all decades of life typically overlooked with standard conventional studies. These cases demonstrate how technology and wearables are reshaping our understanding of metabolic health in an era where patients think they are doing all the right things, and yet are still sick under the surface. |
| 3:00 – 3:45 pm | Break/Visit Exhibits |
| 3:45 – 4:30 pm | Update of Senolytics and Rapamcyin in Reducing Biological Aging Edwin Lee, M.D. Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Member, AMMG Planning CommitteeIs there a pill that can make you biologically younger? As longevity science advances, much attention has focused on senescent cells, cell cycle arrest, and the role of the senescence-associated secretory phenotype (SASP) in aging. Rapamycin has demonstrated lifespan extension in rodents and other species, leading to widespread off-label use in wellness settings, and emerging data on its effects on biological age will be reviewed; however, because SASP also contributes to anti-inflammatory signaling, tissue repair, regeneration, and tumor suppression, suppressing it in healthy individuals may not be beneficial and could potentially accelerate aspects of aging. Similarly, Fisetin—along with other senolytics such as dasatinib and quercetin—has shown promise in animal studies, yet human data, particularly in healthy cohorts, have not replicated those results, with one study showing an increase in biological age in 50% of participants. These findings suggest that while senolytics and mTOR modulation may have therapeutic roles in individuals with significant senescent cell burden or age-related disease, they are not one-size-fits-all interventions and may pose risks when used indiscriminately in otherwise healthy populations. |
| 4:30 – 5:30 pm | Serial Therapeutic Plasma Exchange: The End of Toxicity a Contemporary Literature Review Pamela W. Smith, M.D., MPH, MS Physician, Center for Precision Medicine, Birmingham, MITherapeutic plasma exchange (TPE) is a blood purification technique which functions to remove pathological plasma constituents such as autoantibodies, inflammatory cytokines, immune complexes, and extracellular vesicles that contribute to a range of disease states. TPE has been available to the medical community for over 50 years. This exciting seminar will review the contemporary literature concerning this most timely subject related to toxin removal and heart disease, oncological diseases, inflammatory disorders, autoimmune processes, and other metabolic dysfunctions. |
| 5:30 – 7:00 pm | AMMG Exhibit Hall Happy Hour
Open to all conference attendees, spouses and guests Held in Conference Networking and Exhibits Center |
Saturday April, 17th
Saturday General Session
– Microbiome Regulation of Human Genome: Applications in Longevity Medicine
– NAD+ Exposed: Fact, Fiction, and the Gray Areas in Between
– Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study
– The New Clinical Frontier: Integrating Peptides and Supplements into Clinical Practice
– The Hidden Role of Lyme & Chronic Vector-Borne Pathogens in Accelerating Biological Aging and Impairing Longevity
– Frustration to Focus: Natural Strategies for ADHD in Older Adults
– Hashimoto’s Thyroiditis Is an Immune Disorder – The Thyroid Is Its Victim: Beyond TSH: Early Detection, Immune Dysregulation, and Thyroid Restoration
– Building an Age Management / Longevity Medicine Practice – Where do I Start ?
AMA CME Credits Offered for Select Courses
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:45 am | Microbiome Regulation of Human Genome: Applications in Longevity Medicine Dushyant Viswanathan, MD, ABIM, ABoIM, AACE Chief Medical Officer, The Columbia Center for Integrative Medicine (CCIM), Columbia, MD & Los Angeles, CA Lecture Description TBA |
| 8:45 – 9:30 am | NAD+ Exposed: Fact, Fiction, and the Gray Areas in Between Elizabeth Yurth, M.D. Co-Founder, CMO, Boulder Longevity Institute, Boulder, CO One of the concerns in the emerging field of longevity medicine is how we can push the envelope to really change the outcome of aging and age-related diseases without doing more harm than good. The body desires to always restore balance or homeostasis. When we disrupt this process in our attempt to help, we may actually cause more disease than we help prevent. This lecture will focus on the use of NAD and its precursors, NMN and NR, which are extremely popular right now. However, using these supplements needs to be done in a much more cautious and calculated manner to avoid damaging the delicate REDOX balance in the cell and causing more disease than we help! Nicotinamide Adenine Dinucleotide (NAD+) is the crucial coenzyme found in all living cells, playing a pivotal role in redox reactions, metabolism, and cellular signaling. The NAD+ redox pathway is fundamental to energy production and homeostasis. NAD+ functions as an electron carrier in metabolic processes, alternating between its oxidized (NAD+) and reduced (NADH) forms. This ability to accept and donate electrons makes NAD+ essential in various biochemical pathways, particularly those involved in the production of ATP, the cell’s primary energy currency. In glycolysis, NAD+ is reduced to NADH as glucose is broken down into pyruvate, generating ATP in the process. Subsequently, in the mitochondria during the citric acid cycle (also known as the Krebs cycle), NAD+ is again reduced to NADH. These NADH molecules then donate electrons to the electron transport chain, a series of protein complexes located in the inner mitochondrial membrane. As electrons pass through these complexes, a proton gradient is established, driving the production of ATP via oxidative phosphorylation. Beyond its role in energy metabolism, NAD+ is integral to cellular signaling and DNA repair, it serves as a substrate for sirtuins, a family of NAD+-dependent deacetylases that regulate gene expression, aging, and stress resistance. NAD+ is also a substrate for poly (ADP-ribose) polymerases (PARPs), which are involved in DNA repair and genomic stability. Moreover, NAD+ influences calcium signaling through its role in the production of cyclic ADP-ribose, a molecule that mobilizes calcium from intracellular stores. The cellular NAD+/NADH ratio is a critical indicator of cellular redox state and metabolic health. High NAD+ levels are associated with enhanced cellular repair and longevity, while a decline in NAD+ levels is linked to aging and various metabolic disorders. Consequently, NAD+ replenishment strategies are extremely popular today. However, is more always better? Are we actually simply feeding degradative enzymes such as CD38 and NNMT by giving NAD and its precursors, which propagate rather than inhibit disease states? By the end of this unique lecture topic, the audience will have a much clearer understanding of the safe use of these compounds, the intricate balance at play inside our cells, and how we can best raise NAD+ levels in the safest way possible using unique peptide modalities and supplements that work in a much more physiologic fashion to restore healthful NAD levels. |
| 9:30 – 10:15 am | Ketamine-Assisted Psychotherapy Provides Lasting and Effective Results in the Treatment of Depression, Anxiety and Post-Traumatic Stress Disorder at 3 and 6 Months: Findings from a Large Retrospective Effectiveness Study Ryan Yermus, MD CCFP FCFP Question: What are the lasting effects of ketamine-assisted psychotherapy (KAP) on psychological distress? Findings: In this retrospective effectiveness study, the sample sizes were 346 and 94 participants at 3 and 6 months, respectively, representing loss to follow-up rates of 82% and 95%. Large effect sizes were found at 3 months on depression, anxiety, and post-traumatic stress (d’s = 0.75–0.86) that were sustained at 6 months. Meaning: These findings suggest that KAP is an effective treatment option with substantial clinical benefits detected for up to half a year. |
| 10:15 – 10:30 am | Break/Visit Exhibits |
| 10:30 – 11:15 am | The New Clinical Frontier: Integrating Peptides and Supplements into Clinical Practice Derrick DeSilva, Jr., M.D. Associate Attending Staff, Raritan Bay Medical Center, Perth Amboy, NJ Board of Directors, American Univ. School of Medicine Aruba Recipient, Alan Mintz Award for Clinical Excellence Peptides and targeted supplements are emerging tools in personalized, evidence-informed care. This talk reviews the mechanistic rationale, quality of evidence, and patient selection for peptides used alongside supplements such as vitamin D, omega-3s, probiotics, and CoQ10. It will focus on practical considerations, including safety, monitoring, and where these interventions may fit within standard clinical pathways. The goal is not replacement, but rational, individualized integration. |
| 11:15 am – 12:00 pm | The Hidden Role of Lyme & Chronic Vector-Borne Pathogens in Accelerating Biological Aging and Impairing Longevity Casey S. Kelley, M.D. Founder & Integrative Medical Director, Woven MD, Chicago, IL Endothelial dysfunction is emerging as a central mechanism linking chronic infection, vascular inflammation, and accelerated biological aging. Persistent vector-borne pathogens—such as Borrelia burgdorferi (Lyme borreliosis), Bartonella spp., Babesia spp., and post-COVID syndromes—induce chronic, low-grade vascular injury that parallels processes seen in aging and age-related disease. Mechanistic studies show that B. burgdorferi upregulates adhesion molecules including E-selectin, VCAM-1, and ICAM-1 in human endothelial cells, promoting immune cell infiltration and endothelial activation. Studies also indicate that B. burgdorferi exposure alters endothelial physical forces and innate immune signaling, transiently increasing intercellular tension and later reducing motility, which may contribute to barrier compromise. In Bartonella henselae, interference with VEGF signaling has been documented: infection impairs VEGFR2 phosphorylation at key tyrosine residues, diminishes downstream pathways (PLCγ, ERK1/2), and suppresses endothelial proliferation and wound healing. Across both pediatric and adult populations, SARS-CoV-2 infection and its post-acute sequelae are associated with elevated biomarkers of endothelial activation—such as angiopoietin-2, soluble E-selectin, and von Willebrand factor antigen—which correlate with vascular inflammation, microvascular dysfunction, and cardiovascular compromise, indicating that COVID-related endothelial injury is both measurable and clinically significant. Chronic endothelial activation and impaired vascular resilience serve as key drivers of “inflammaging”—the progressive, smoldering inflammation that underlies cardiovascular disease, neurodegeneration, and loss of physiological reserve. This talk proposes a unified model in which chronic infections accelerate biological aging by inducing endothelial cell activation, oxidative stress, mitochondrial injury, and impaired repair signaling. Understanding these pathways offers promising targets for early diagnostics (e.g. biomarkers of endothelial activation) and intervention to prevent infection-driven vascular aging and preserving cellular resilience across the lifespan. |
| 12:00 – 1:30 pm | Lunch Break/Visit Exhibits |
| 12:00 – 12:45 pm | Lunch |
| 1:30 – 2:15 pm | Frustration to Focus: Natural Strategies for ADHD in Older Adults Peter B. Bongiorno, N.D., LAc Owner, Bongiorno Consulting Attention-Deficit/Hyperactivity Disorder (ADHD) is now recognized as a condition that often persists into older adulthood, yet conventional stimulant and non-stimulant medications may pose greater risks in this population, including cardiovascular effects, sleep disruption, and mood instability. These approaches also frequently overlook the underlying contributors to symptoms. Dr. Bongiorno will present the benefits and challenges of medications,and then explain the naturopathic approach for supporting ADHD in the aging population, focusing on identifying root causes through targeted lab testing and individualized care. Kep topics include the impact of nutrient deficiencies, metabolic and hormonal changes, chronic inflammation, and lifestyle factors such as sleep quality, blood sugar regulation, stress and diet. Evidence-based use of nutraceuticals and botanicals to enhance attention, mood, and cognition will also be discussed. |
| 2:15 – 3:00 pm | Hashimoto’s Thyroiditis Is an Immune Disorder – The Thyroid Is Its Victim: Beyond TSH: Early Detection, Immune Dysregulation, and Thyroid Restoration William Clearfield, D.O. Medical Director, Clearfield Family Medicine, Reno, NV Executive Director, American Osteopathic Society of Rheumatic Diseases Adjunct Professor, Arkansas College of Osteopathic Medicine; University of Guadalajara School of Medicine Hashimoto’s thyroiditis is an autoimmune disease. Hashimoto’s thyroiditis is a thyroid disease. ‘Conventional’ medical management focuses on the thyroid gland, the victim of Hashimoto’s immune-mediated injury, ignoring the autoimmune process responsible for its destruction. ‘Conventional’ treatment centers on thyroid hormone replacement after thyroid dysfunction develops. Although hormone replacement is essential when indicated, waiting for the thyroid to fail before addressing the underlying autoimmune disorder overlooks years of disease activity and opportunities for earlier intervention. In Hashimoto’s thyroiditis, the immune system targets thyroid tissue, initiating chronic inflammation and progressive glandular destruction. Hypothyroidism represents the end consequence, not the initiating event. In a retrospective review of new patients evaluated in my practice from 2017 through 2023, 28% had positive thyroid antibodies without their prior knowledge of thyroid autoimmunity. Patients report symptoms of hypothyroidism, fatigue, weight gain, cognitive dysfunction, depression, hair loss, constipation, cold intolerance, infertility, and reduced quality of life despite thyroid laboratory values within reference ranges. These symptoms necessitate investigation for thyroid dysfunction, associated autoimmune conditions, metabolic abnormalities, and nutritional deficiencies rather than just a knee jerk reaction to thyroid function only. Drawing on current scientific literature and nearly five decades of clinical experience, I examine the five-stage progression of Hashimoto’s thyroiditis from immune activation to thyroid dysfunction and the implications of immune optimization, hormone optimization and long-term health. This presentation reviews the complete thyroid laboratory cascade, TSH, free T4, free T3, reverse T3, thyroid peroxidase and thyroglobulin antibodies, and less commonly assessed antibodies involving the TSH receptor, sodium-iodide symporter, pendrin, thyroid hormones, and other thyroid-cell proteins. Special emphasis is placed on diagnostic indications, clinical interpretation, and the limitations of expanded testing. To make this a must, take home and refer to it often lecture, I introduce the “Hashimoto’s Octopus,” an eight-domain model illustrating the interrelationships between immune regulation, nutrition, micronutrients, gastrointestinal health, stress physiology, environmental factors, hormonal and metabolic health, and thyroid restoration. To complete the picture, I discuss the roles of iodine, selenium, iron, vitamin D, zinc, magnesium, B vitamins, gastrointestinal disorders, intestinal permeability, and environmental exposures, distinguishing established clinical findings from emerging diagnostic and therapeutic approaches. A clinical case is used as the vehicle through the Hashimoto’s maze, following a real-life patient, “The Grizz,” with ten years of persistent symptoms despite thyroid laboratory values within reference ranges. The Grizz’s case examines the failures of the conventional medical model, diagnostic decisions, associated autoimmune and metabolic conditions, nutritional status, thyroid hormone treatment, and individualized patient follow-up. Participants leave with a clinical framework for recognizing autoimmune thyroid disease before overt hypothyroidism takes hold, selecting appropriate diagnostic studies, evaluating persistent symptoms, and integrating thyroid hormone replacement with management of associated conditions and documented deficiencies. |
| 3:00 – 3:45 pm | Break/Visit Exhibits (Exhibits Close at 4:00pm) |
| 3:45 – 4:30 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 4:30 – 5:30 pm | Building an Age Management / Longevity Medicine Practice – Where do I Start ? Moderator/Panelist: Derrick DeSilva, Jr., M.D. Panelist: Luis Martinez, M.D. Panelist: Elliott Dinetz, M.D. Panelist: James Powell, RN Each panelist will be prepared to provide information and discuss what attendees can do Monday morning to set up an Age Management / Longevity Medicine Practice. In addition audience participation is encouraged, engage with these clinicians already in practice and ask your questions. The goal is to give attendees a basic blue print for adding or converting their practice to this 21st Century preventive approach to medicine. Lecture Description TBA |
Thursday, April 18th
Workshop: Advanced Peptide Clinical Strategies: Protocols, Dosages, Case Discussion - Part 2
The Advanced Clinical Peptide Workshop is an intensive, physician-focused educational program designed for clinicians seeking deeper expertise in evidence-informed peptide therapeutics and integrative regenerative medicine. This immersive workshop will explore advanced peptide protocols across metabolic optimization, body composition, recovery, neurocognitive health, sexual wellness, longevity medicine, and performance enhancement, with emphasis on mechanism-driven clinical application, patient selection, dosing strategies, stacking approaches, safety considerations, and treatment sequencing. Attendees will participate in interactive case-based discussions that simulate real-world clinical decision-making, allowing participants to analyze complex patient scenarios, troubleshoot therapeutic responses, and refine individualized treatment plans alongside experienced faculty and peers. The program will also address the evolving regulatory and compliance landscape surrounding peptide prescribing, compounding, documentation, informed consent, and state and federal oversight, helping clinicians integrate peptide therapies into practice with greater confidence, sophistication, and operational clarity.
PREREQUISITE REQUIREMENT: Submit 2-3 cases studies to AMMG before the meeting. Must have completed an AMMG Full Day Initial Peptide Course and/or Peptide Certification. The Peptide Certification on Wednesday October 7th will satisfy this requirement as would any previous AMMG Peptide Full Day Course.
Non-CME Workshop
TOPICS INCLUDE:
– Before the First Peptide
– For The First Time, Previously Unavailable Russian Scientific Literature on Semax and Epitalon Translated into English
– Clinical Case Presentation – Part 1
– Clinical Case Presentation – Part 2
– Artificial Intelligence Derived Peptides
– Regulatory Landscape of Peptides
– Interactive Attendee Case Studies – Part 1
– Novel & Emerging Peptides
– Peptides that Passed the February, 2027 Pharmacy Compounding Advisory Committee Meeting
– Interactive Attendee Cases – Part 2
– Lessons Learned from Being Issued a 483 from the FDA for Doing Peptide Research
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:05 am | Welcome and Introduction Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee |
| 8:05 – 8:35 am | Before the First Peptide Edwin Lee, MD, FACE Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Why Nutrition, Sleep, Exercise, the Microbiome, Environmental Health, and Hormonal Balance Determine the Success of Peptide Therapy |
| 8:35 – 9:05 am | For The First Time, Previously Unavailable Russian Scientific Literature on Semax and Epitalon Translated into English Edwin Lee, MD, FACE Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee These publications provide valuable insight into the original research and help address longstanding questions regarding the 5 mg subcutaneous Epitalon dosing regimen administered over 10 days. Also, the athletic performance and other conditions with Semas will be reviewed. |
| 9:05 – 9:30 am | Clinical Case Presentations – Part 1 Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee • 3–5 Advanced Cases |
| 9:30 – 9:45 am | Break |
| 9:45 – 10:30 am | Clinical Case Presentations – Part 2 Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee • Metabolic & longevity cases |
| 10:30 – 11:00 am | Artificial Intelligence Derived Peptides Edwin Lee, MD, FACE Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Peptides discovered by artificial intelligence (AI) through screening more than one billion plant-derived peptides and subsequently tested in human clinical trials. |
| 11:00 am – 12:00 pm | Regulatory Landscape of Peptides Faculty TBA • FDA trends |
| 12:00 – 1:30 pm | Lunch Break |
| 1:30 – 2:15 pm | Interactive Attendee Case Studies – Part 1 Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Edwin Lee, MD, FACE Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee • Case submissions prior to the meeting – try to focus on 2-3 issues instead of 20 issues |
| 2:15 – 3:15 pm | Novel & Emerging Peptides Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee • Pipeline peptides |
| 3:15 – 3:30 pm | Break |
| 3:30 – 3:45 pm | Peptides that Passed the Feb 2027 Pharmacy Compounding Advisory Committee Meeting Edwin Lee, MD, FACE Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Lecture Description TBA |
| 3:45 – 4:30 pm | Interactive Attendee Case Studies – Part 2 Luis Martínez, M.D., MPH President, XanoGene Clinics, San Juan and Ponce Puerto Rico President, Caribbean AntiAging Medicine Association Co-Founder, Clinical Peptide Society Founder, Senolytic Therapy Network Medical Director, Aluma Wellness and Hormone Therapy of Orlando Medical Director, Body Rejuvenation, Miami, Florida Member, AMMG Planning Committee Edwin Lee, MD, FACE Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Lecture Description TBA |
| 4:15 – 4:30 pm | Lessons Learned from Being Issued a 483 from the FDA for Doing Peptide Research Edwin Lee, MD, FACE Assistant Professor of Internal Medicine, University of Central Florida College of Medicine Co-Founder, Clinical Peptide Society Recipient, Alan Mintz Award for Clinical Excellence Member, AMMG Planning Committee Lecture Description TBA |
Sunday, April 18th
WOrkshop: The Neurotrauma Masterclass-Understanding, Assessing and Treating Traumatic Brain Injury
The Updated 2026 Traumatic Brain Injury Lecture Series is a seven-chapter educational journey designed to follow traumatic brain injury from the moment mechanical forces affect the brain through the complex biological processes that can determine long-term neurological health and recovery. Rather than viewing TBI as a single event or treating its aftermath as a collection of unrelated symptoms, this series examines the biological continuum of brain injury. It begins with the mechanical forces of concussion and repetitive subconcussive trauma and follows their effects through mechanotransduction, neurological disruption, neuroinflammation, oxidative stress, mitochondrial dysfunction, neuroendocrine dysregulation, and neuropsychiatric change. The series then moves from mechanism to measurement, demonstrating how comprehensive laboratory assessment can help uncover biological abnormalities that may remain hidden when evaluation is based solely upon symptoms, conventional imaging, or standard laboratory reference ranges. Finally, these concepts are brought together in a treatment-focused discussion addressing how identification of the underlying biological mechanisms can help guide an individualized strategy designed to reduce inflammation, restore neuroendocrine balance, support cellular and mitochondrial function, and create a more neuropermissive environment for recovery. The goal is to provide attendees with a new framework for understanding TBI, one that moves beyond asking only “What symptoms does this person have?” toward the more important questions: “What happened biologically, what is continuing to drive the symptoms, what can we measure, and what can we do about it?”
THE CONTINUUM FROM NEUROTRAUMA TO RECOVERY: INJURY → NEUROLOGY → INFLAMMATION → NEUROENDOCRINOLOGY → PSYCHIATRY → LABORATORY → TREATMENT – Understand the Injury. Identify the Biology. Measure the Dysfunction. Address the Cause. Support the Recovery
TOPICS INCLUDE:
– Introduction to Traumatic Brain Injury
– The Neurology of Traumatic Brain Injury
– Inflammatory Responses in Traumatic Brain Injury
– Neuroendocrinology of Traumatic Brain Injury
– Psychiatry and Traumatic Brain Injury
– The Laboratory of Traumatic Brain Injury
– Treatment of Traumatic Brain Injury: Treatment Protocol
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:40 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 8:40 – 9:20 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 9:20 – 10:00 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 10:00 – 10:15 am | Break |
| 10:15 – 11:15 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 11:15 am – 12:00 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 12:00 – 1:00 pm | Lunch Break |
| 12:00 – 12:45 pm | Lunch |
| 1:00 – 1:40 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 1:40 – 2:30 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 2:30 – 2:45 pm | Break |
| 2:45 – 3:30 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 3:30 – 4:15 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 4:15 – 5:15 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 5:15 – 5:30 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
Sunday, April 18th
Workshop: Artificial Intelligence in Longevity Medicine
Many attendees of the AMMG conferences are attracted to the field of Age Management Medicine, but do not feel qualified, or empowered with the necessary tools, to successfully transition from the well-established structure of disease-based medicine or from the traditional insurance-based reimbursement system into a system which relies to a significant degree upon direct pay. In addition, this workshop is also designed to complement the AMMG Certification in Age Management Medicine for physicians and healthcare professionals and to help educate and inform medical and office staff. Attendees will be guided through the process of developing or growing an Age Management Practice. Our goal is for the attendee to be equipped with the basic tools for making the necessary decisions on what is required from a Practice Management point of view.
TOPICS INCLUDE:
– Foundations of Artificial Intelligence and the Biology of Aging
– AI Based Biomarker Assessment and Biological Age Measurement
– Clinical AI Applications in a Longevity/Age Management Medicine Practice: What Can I use in My Practice Monday Morning?
– Ethics, Regulation, Equity and Practice Integration
Time |
Presentation |
|---|---|
| 7:15 am | Early Morning Coffee & Hot Tea Provided |
| 8:00 – 8:40 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 8:40 – 9:20 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 9:20 – 10:00 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 10:00 – 10:15 am | Break |
| 10:15 – 11:15 am | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 11:15 am – 12:00 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 12:00 – 1:00 pm | Lunch Break |
| 12:00 – 12:45 pm | Lunch |
| 1:00 – 1:40 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 1:40 – 2:30 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 2:30 – 2:45 pm | Break |
| 2:45 – 3:30 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 3:30 – 4:15 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 4:15 – 5:15 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
| 5:15 – 5:30 pm | Lecture Title TBA Faculty TBA Lecture Description TBA |
